Prostate cancer in 2011: Hitting old targets better and identifying new targets.

ABSTRACT: Options to treat late-stage castration-resistant prostate cancer continued to increase in 2011, as three agents with different mechanisms of action prolonged life and a fourth reduced the morbidity of skeletal metastases. These outcomes contrasted with the heightened controversy generated by the recommendation against PSA screening and other early detection strategies.

SUBMITTER: Chen Y 

PROVIDER: S-EPMC5572096 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature